FinalTitles
stringlengths 1
414
⌀ |
---|
The dual role of CD70 in B-cell lymphomagenesis. |
Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan. |
Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report. |
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. |
Identifying the Effect of COVID-19 Infection in Multiple Myeloma and Diffuse Large B-Cell Lymphoma Patients Using Bioinformatics and System Biology. |
Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma. |
Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities. |
Plasmablastic Lymphoma of the Endometrium: A Rare Site for Primary Presentation. |
Anti-spike antibody response to the COVID vaccine in lymphoma patients. |
Case report and review of the literature of primary central nervous system lymphoma of the fourth ventricle. |
Plasmablastic Lymphoma in an Immunocompetent Patient: A Case Report and Literature Review. |
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. |
Diabetes, Metformin Use, and Risk of Non-Hodgkin's Lymphoma in Postmenopausal Women: A Prospective Cohort Analysis in the Women's Health Initiative. |
Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients. |
null |
Primary sinonasal lymphoma: A multi-institutional experience of clinical presentation, treatment, and outcomes. |
null |
Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis. |
How I treat Elderly Patients with DLBCL in the frontline setting. |
Hemophagocytic lymphohistiocytosis secondary to diffuse large B-cell lymphoma presenting with recurrent multi-territory infarcts: A case report. |
Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma. |
Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors. |
Oral Chemotherapy Application in Elderly Patients With Diffuse Large B-Cell Lymphoma: An Alternative Regimen in Retrospective Analysis. |
Immunophenotypic characterisation of non-Hodgkin lymphomas at a tertiary hospital in Ghana. |
Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. |
Molecular and clinical diversity in primary central nervous system lymphoma. |
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey. |
Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma. |
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. |
null |
Concomitant Presence of Spermatic Cord and Testicular Non-Hodgkin's Lymphoma With Recurrence: A Case Report on a Rare Entity. |
B cell lymphoma 6A regulates immune development and function in zebrafish. |
Identification of ATP1B1, a key copy number driver gene in diffuse large B-cell lymphoma and potential target for drugs. |
null |
Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma. |
Clinicopathological Spectrum of Cutaneous Lymphomas and Distinction of Early Mycosis Fungoides from its Mimics-A Retro-Prospective Descriptive Study from Southern India. |
Clinico-Dermoscopic-Pathological Features of a Rare Case of Locally Invasive Multifocal Primary Cutaneous Diffuse Large B Cell Lymphoma-Leg Type Over the Face and Scalp. |
Prostate primary intravascular large B-cell lymphoma: A case report. |
Interim FDG-PET/CT for Response Assessment of Lymphoma. |
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. |
Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience. |
Clinical application of 3D Slicer combined with Sina/MosoCam multimodal system in preoperative planning of brain lesions surgery. |
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. |
Development of combinatorial antibody therapies for diffuse large B cell lymphoma. |
Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment. |
Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. |
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. |
Poly zinc finger protein ZFP14 suppresses lymphomagenesis and abnormal inflammatory response via the HOXA gene cluster. |
Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition. |
A Novel Prognostic Model for Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. |
Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study. |
Primary diffuse large B-cell lymphoma of the right kidney: a case report. |
High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma. |
A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma. |
An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study. |
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. |
Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma. |
Recurrent chylous ascites in patient with previous retroperitoneal radiation treatment. |
Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials. |
IGH/BCL2 Status Better Predicts Clinico-Pathological Behavior in Primary Splenic Follicular Lymphoma than Histological Grade and Other Molecular Markers. |
Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma. |
Automated data preparation for |
Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing. |
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. |
Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. |
Identification and molecular analysis of RNF31 Q622H germline polymorphism. |
Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma. |
Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. |
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy. |
A rare primary pericardial DLBCL masquerading as an unexplained malignant pleural effusion in an elderly woman: A case report. |
A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma. |
Garcin syndrome in a case of acquired immunodeficiency syndrome. |
ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. |
Analysis of the Correlation of Basic Fibroblast Growth Factor in Serum of Patients with Diffuse Large B-Cell Lymphoma with Clinicopathological Efficacy and International Prognostic Index. |
Different expression of DNMT1, PCNA, MCM2, CDT1, EZH2, GMNN and EP300 genes in lymphomagenesis of low vs. high grade lymphoma. |
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. |
Follicular lymphoma: 2023 update on diagnosis and management. |
Bullous lichen sclerosus-generalized morphea overlap syndrome improved by tofacitinib. |
Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. |
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. |
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study. |
Validation of the |
Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report. |
Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy. |
CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway. |
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma. |
Primary Spinal Epidural Diffuse Large B-cell Lymphoma: Case Report and Literature Review. |
Scaffold-mediated switching of lymphoma metabolism in culture. |
Acute kidney injury after CAR-T cell infusion. |
Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era. |
Circulating Tumor DNA in Lymphoma. |
Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma. |
Diagnosis of rapidly progressed primary cardiac lymphoma in liver transplant recipient: A case report. |
Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form. |
Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. |
Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry. |
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. |
Herbicide use in farming and other jobs in relation to non-Hodgkin's lymphoma (NHL) risk. |
Palbociclib enhances the effect of doxorubicin-induced apoptosis in activated B-cell-like diffuse large B-cell lymphoma cells. |
Splenocolic fistula in a patient with diffuse large B-cell lymphoma: A case report and review of literature. |